Kelly Lancaster
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kelly Lancaster has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Dorin Toader
Mersana Therapeutics, Inc., Cambridge, Massachusetts
44 shared publications - Elizabeth Ditty
Mersana Therapeutics, Inc., Cambridge, Massachusetts
44 shared publications - Jeffrey Zurita
Mersana Therapeutics, Inc., Cambridge, Massachusetts
44 shared publications - Kalli C. Catcott
Mersana Therapeutics, Inc., Cambridge, Massachusetts
44 shared publications - Ling Xu
Mersana Therapeutics, Inc., Cambridge, Massachusetts
44 shared publications - Marc Damelin
Mersana Therapeutics, Inc., Cambridge, Massachusetts
44 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Table S3. HER2 expression in cell lines and tumor xenografts, including gene expression by RNAseq (log2 transformed); binding EC50 and maximal fluorescence intensity (Bmax FL) of XMT-2056 by flow cytometry, and HER2 immunohistochemistry in tumor xenografts. EC50 and Bmax values represent mean of 2 independent experiments.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Table S3. HER2 expression in cell lines and tumor xenografts, including gene expression by RNAseq (log2 transformed); binding EC50 and maximal fluorescence intensity (Bmax FL) of XMT-2056 by flow cytometry, and HER2 immunohistochemistry in tumor xenografts. EC50 and Bmax values represent mean of 2 independent experiments.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Figure S7. A. CB.17 SCID mice bearing subcutaneous JIMT-1 xenograft tumors were administered 3 weekly doses of XMT-2056, a combination of non-binding control ADC and pertuzumab, or a combination of XMT-2056 and pertuzumab. B. CB.17 SCID mice bearing subcutaneous SNU-5 xenograft tumors were administered a single dose of XMT-2056, non-binding control ADC, pertuzumab, or a combination of XMT-2056 and pertuzumab. ADCs were administered intravenously while pertuzumab was administered intraperitoneally. Each point represents the mean tumor volume and SEM (n=10).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Figure S7. A. CB.17 SCID mice bearing subcutaneous JIMT-1 xenograft tumors were administered 3 weekly doses of XMT-2056, a combination of non-binding control ADC and pertuzumab, or a combination of XMT-2056 and pertuzumab. B. CB.17 SCID mice bearing subcutaneous SNU-5 xenograft tumors were administered a single dose of XMT-2056, non-binding control ADC, pertuzumab, or a combination of XMT-2056 and pertuzumab. ADCs were administered intravenously while pertuzumab was administered intraperitoneally. Each point represents the mean tumor volume and SEM (n=10).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Figure S8. A, B. BALB/c immune competent mice bearing syngeneic EMT-6-rHER2 tumors were treated with XMT-2056 surrogate ADC, anti-mouse PD-1 (Clone RPM1-14), non-binding control ADC in combination with anti-mouse PD-1, or XMT-2056 surrogate ADC in combination with anti-mouse PD-1. The ADCs were administered once while the mouse anti-PD-1 was administered twice weekly for 2 weeks as indicated by the red triangles. A. Tumor volumes of the individual mice, with the number of complete responders (CR) indicated. B. Percent change in body weight (BW). Each point represents the mean change in BW and SEM (n=10).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Figure S8. A, B. BALB/c immune competent mice bearing syngeneic EMT-6-rHER2 tumors were treated with XMT-2056 surrogate ADC, anti-mouse PD-1 (Clone RPM1-14), non-binding control ADC in combination with anti-mouse PD-1, or XMT-2056 surrogate ADC in combination with anti-mouse PD-1. The ADCs were administered once while the mouse anti-PD-1 was administered twice weekly for 2 weeks as indicated by the red triangles. A. Tumor volumes of the individual mice, with the number of complete responders (CR) indicated. B. Percent change in body weight (BW). Each point represents the mean change in BW and SEM (n=10).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Figure S2. A. STING mediated IRF3 activity of THP1 reporter cells expressing the indicated human STING1 haplotypes or STING1 knockout (KO) after treatment with STING agonist at the indicated doses. Each point represents the mean and SD (n=2). B. Cytokine induction as measured by a multiplex Luminex assay from supernatants of fresh human white blood cells treated for 6 (IFN-β) or 24 (CXCL10, IL-6, TNF-α) hours with indicated concentrations of STING agonist. Bars represent mean value of n=2 data points shown as symbols. C. Structure of the human HER2 extracellular domain showing HT19 epitope mapped to domain IV through shotgun mutagenesis using an Alanine Scanning Mutagenesis. D. Lack of competition with pertuzumab by bio-layer interferometry binning assay (Octet). Pertuzumab was loaded onto the sensor chip, and HER2 ECD and HT19 associations indicated by blue arrows. Additional binding by HT19 antibody indicates non-competitive binding. E. HER2+ NCI-N87 gastric cancer xenograft model treated with Dolaflexin (DF)-based ADCs including conjugates of trastuzumab or non-binding isotype control ADC at the indicated doses. Each point represents mean tumor volume and SEM (n=10). F. Bar graphs of % inhibition in phospho-AKT in SKBR3 cells for HT19, trastuzumab, and lapatinib. Each bar represents mean and SD of 2 independent experiments. G. Binding of XMT-2056, HT19, and hIgG1 isotype control antibody to SKBR3, JIMT-1, MDA-MB-453, SNU-5, and MDA-MB-175-VII cells showing fluorescence intensities measured by flow cytometry. Each point represents mean and SD (n=3). H. Graphical traces of binding kinetics of XMT-2056, HT19, or Fc mutant XMT-2056 to human Fcγ-RI recombinant protein, showing association and dissociation phases of binding by Octet. I. IRF3 reporter activity of THP1 cells in monoculture (Ieft) or cultured in plates in the absence of HER2 antigen (right) treated for 24 hours with XMT-2056, Fc mutant XMT-2056, non-binding control ADC, or free payload. Each point represents mean and SD (n=3).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Figure S2. A. STING mediated IRF3 activity of THP1 reporter cells expressing the indicated human STING1 haplotypes or STING1 knockout (KO) after treatment with STING agonist at the indicated doses. Each point represents the mean and SD (n=2). B. Cytokine induction as measured by a multiplex Luminex assay from supernatants of fresh human white blood cells treated for 6 (IFN-β) or 24 (CXCL10, IL-6, TNF-α) hours with indicated concentrations of STING agonist. Bars represent mean value of n=2 data points shown as symbols. C. Structure of the human HER2 extracellular domain showing HT19 epitope mapped to domain IV through shotgun mutagenesis using an Alanine Scanning Mutagenesis. D. Lack of competition with pertuzumab by bio-layer interferometry binning assay (Octet). Pertuzumab was loaded onto the sensor chip, and HER2 ECD and HT19 associations indicated by blue arrows. Additional binding by HT19 antibody indicates non-competitive binding. E. HER2+ NCI-N87 gastric cancer xenograft model treated with Dolaflexin (DF)-based ADCs including conjugates of trastuzumab or non-binding isotype control ADC at the indicated doses. Each point represents mean tumor volume and SEM (n=10). F. Bar graphs of % inhibition in phospho-AKT in SKBR3 cells for HT19, trastuzumab, and lapatinib. Each bar represents mean and SD of 2 independent experiments. G. Binding of XMT-2056, HT19, and hIgG1 isotype control antibody to SKBR3, JIMT-1, MDA-MB-453, SNU-5, and MDA-MB-175-VII cells showing fluorescence intensities measured by flow cytometry. Each point represents mean and SD (n=3). H. Graphical traces of binding kinetics of XMT-2056, HT19, or Fc mutant XMT-2056 to human Fcγ-RI recombinant protein, showing association and dissociation phases of binding by Octet. I. IRF3 reporter activity of THP1 cells in monoculture (Ieft) or cultured in plates in the absence of HER2 antigen (right) treated for 24 hours with XMT-2056, Fc mutant XMT-2056, non-binding control ADC, or free payload. Each point represents mean and SD (n=3).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Figure S1. Characterization of XMT-2056
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Figure S1. Characterization of XMT-2056
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Figure S6. FVB/NJ immune competent mice bearing syngeneic mBR9013 subcutaneous tumors were intravenously administered anti-mouse PD-1 (clone RPM1-14) 10 mg/kg twice weekly for 3 weeks (red triangles). Each point represents the mean tumor volume and SEM (n=5).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Figure S6. FVB/NJ immune competent mice bearing syngeneic mBR9013 subcutaneous tumors were intravenously administered anti-mouse PD-1 (clone RPM1-14) 10 mg/kg twice weekly for 3 weeks (red triangles). Each point represents the mean tumor volume and SEM (n=5).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Table S2. EC50 values for binding of XMT-2056 or HT19 antibody to human and nonclinical species HER2 extracellular domain. Highest dose tested is 100 nM by antibody. Values represent mean of 2 independent experiments.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Table S2. EC50 values for binding of XMT-2056 or HT19 antibody to human and nonclinical species HER2 extracellular domain. Highest dose tested is 100 nM by antibody. Values represent mean of 2 independent experiments.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Figure S3. A. Cancer cell death induced by XMT-2056, HT19 antibody, or non-binding control ADC, shown as percent viable SKBR3-NR (left) or MDA-MB-175-VII-NR (right) cells in PBMC co-cultures (84 hr time point). Each point represents mean and SD (n=3). B. Cytokine induction by XMT-2056, HT19, or non-binding control ADC measured in supernatants of SKBR3-NR (top) or MDA-MB-175-VII-NR (bottom) cells in PBMC co-cultures (24 hr time point). Each point represents mean and SD (n=3). C. Cancer cell death by XMT-2056, non-binding control ADC, or STING agonist payload shown as percent viable cells in monocultures of MDA-MB-231-NR (left) and SKBR3-NR (right) (84 hr time point). Each point represents mean and SD (n=3).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Figure S3. A. Cancer cell death induced by XMT-2056, HT19 antibody, or non-binding control ADC, shown as percent viable SKBR3-NR (left) or MDA-MB-175-VII-NR (right) cells in PBMC co-cultures (84 hr time point). Each point represents mean and SD (n=3). B. Cytokine induction by XMT-2056, HT19, or non-binding control ADC measured in supernatants of SKBR3-NR (top) or MDA-MB-175-VII-NR (bottom) cells in PBMC co-cultures (24 hr time point). Each point represents mean and SD (n=3). C. Cancer cell death by XMT-2056, non-binding control ADC, or STING agonist payload shown as percent viable cells in monocultures of MDA-MB-231-NR (left) and SKBR3-NR (right) (84 hr time point). Each point represents mean and SD (n=3).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Figure S5. A. PK profile of XMT-2056 in non-tumor bearing CB.17 SCID mice as a function of total antibody (Total Ab) and conjugated drug concentrations in plasma after a single intravenous administration. Each line represents an individual animal (n=4). B. PK profile of XMT-2056 in cynomolgus monkey as a function of total antibody and conjugated drug concentrations in plasma during Q3W repeat-dose administration indicated by the black arrowheads. 1 male and 1 female animal were dosed; each line represents data from one animal.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Figure S5. A. PK profile of XMT-2056 in non-tumor bearing CB.17 SCID mice as a function of total antibody (Total Ab) and conjugated drug concentrations in plasma after a single intravenous administration. Each line represents an individual animal (n=4). B. PK profile of XMT-2056 in cynomolgus monkey as a function of total antibody and conjugated drug concentrations in plasma during Q3W repeat-dose administration indicated by the black arrowheads. 1 male and 1 female animal were dosed; each line represents data from one animal.